RxDoctor Payments Data

Qasim Chaudhry

Transplant Surgery · Des Moines, IANPI 1821252750

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (44.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 49.6% of the total. Reporting peaked in 2020 at $8,021 and has fallen 99.7% since, to $21 in 2025.

$12,475in general payments, 2019–2025

Across 54 payments — averaging $231.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$6K
  • Intuitive Surgical$4K
  • Transmedics, Inc.$2K
  • AbbVie$87
  • Merck$39
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30
  • plus $57 from 3 others
$2,159in research payments, 2019–2025

Across 26 payments — averaging $83.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$2K

What the payments were for

  • Speaking & faculty fees$5,40043%
  • Travel & lodging$5,54144%
  • Food & beverage$1,52212%
  • Education$40%
  • Gifts$90%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$212,081
Medicare patients
120
Services billed
1,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Valganciclovir Hcl127$15,121
Mycophenolic AcidMycophenolate Sodium27$12,200
Tacrolimus24$6,407
Enoxaparin Sodium62$3,513
Rosuvastatin Calcium72$1,865
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim228$1,575
Nystatin49$1,176
Famotidine195$1,053
Prednisone193$955
Bumetanide32$842
Amlodipine Besylate136$523
Carvedilol101$505
Nifedipine ErNifedipine14$486
Hydralazine Hcl39$445
Cinacalcet Hcl16$442

Paid to pharmacies, not to this prescriber.

Other transplant surgery in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →